Therefore, future optimization of PRRT should aim to increase tumor cell Fas expression to potentially enhance tumor susceptibility to FasL mediated immune killing by FasL expressing NK cells and CD8+ CTLs. The gene discussed is FASLG; the disease is neoplasm.